エリスロポエチンのグローバル市場動向

【英語タイトル】Global Erythropoietin Market Outlook 2020

RNCOSが出版した調査資料(RNCS507152)・商品コード:RNCS507152
・発行会社(調査会社):RNCOS
・発行日:2015年7月
・ページ数:45
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD400 ⇒換算¥41,600見積依頼/購入/質問フォーム
Multi User(全社内共有可)USD800 ⇒換算¥83,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートでは、エリスロポエチンのグローバル市場動向について調査・分析し、エリスロポエチンの世界市場動向、成長要因、市場の課題、エリスロポエチン市場規模、用途別分析、地域別分析・市場規模、競争環境、主要企業分析などの情報をお届けいたします。
【レポートの概要】

Erythropoietin (EPO) treatment is an innovative technique to regulate red blood cells in a human body. The global erythropoietin industry has been languishing over the past few years and presenting very limited opportunities to the industry players. However, with favourable demographics, positive eco-financial dynamics, rising incidence of cancer and anemia, and rising awareness, the global erythropoietin market is expected to scale newer heights.

The latest research by RNCOS titled “Global Erythropoietin Market Outlook 2020”, unfolds the market dynamics of the erythropoietin market. In this report, the global erythropoietin industry has been split into five distinct drugs: Procrit, NeoRecormon, Mircera, Epogen, and Ararnesp, depicting their current outlook. The report identifies and highlights the drug that offers the maximum opportunity for growth in the global market.

Our industry analysts studied all the facets of the global erythropoietin market to portray a crystal-clear picture of the current as well as the expected future market outlook. Major drivers such as changing lifestyle, increasing incidence of chronic diseases, increasing affordability, and trends such as effective delivery methods and importance of intellectual property rights have been identified. These will act as catalysts toward boosting the industry’s growth.

The report further highlights the competitive landscape of the global erythropoietin market, describing the business, financials, strengths and weaknesses, and recent developments of the major industry players. This will help the reader gain crucial insights into the key market players’ performances and strategies for growth. Holistically, the research provides all the prerequisite information for clients looking to make a debut in this industry and facilitates them to formulate schemes while going for an investment/partnership in the global erythropoietin industry.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Industry Trends and Drivers
3.1 Increasing Incidence of Chronic Diseases
3.2 Increasing Affordability
3.3 Changing Lifestyles
3.4 Effective Delivery Methods: Improving the Reach of Therapy
4. Challenges
4.1 High Prices
4.2 Numerous Drugs Patent Expiries Provide Opportunity for Biosimilars
5. Global Protein Therapeutics Market
5.1 Protein Therapeutics Market Vs Pharmaceutical Market
5.2 Current and Future Market Analysis for 2020
5.2.1 Market Segmentation
6. Erythropoietin Market – Introduction
7. Global Erythropoietin Market Outlook to 2020
8. Market Segmentation
8.1 By Application
8.2 By Geographical Markets
8.3 By Drugs
9. Competitive Landscape
9.1 Share of Major Players
9.2 Key Players
9.2.1 Roche Group
9.2.2 Amgen Inc.
9.2.3 Johnson & Johnson

List of Figures:

Figure 5-1: Global – Protein Therapeutics vs Pharmaceutical Market (Billion US$), 2014
Figure 5-2: Global – Protein Therapeutics Market (Billion US$), 2014-2020
Figure 5-3: Global – Protein Therapeutics Market by Segment (%), 2014
Figure 7-1: Global – Erythropoietin Market (Billion US$), 2014-2020
Figure 8-1: Global – Number of Patients on Dialysis (Million), 2012-2014
Figure 8-2: Global – Breakup of Patients on Dialysis by Region (%), 2013
Figure 8-3: Global – Number of New Cancer Cases (Million), 2012 & 2030
Figure 8-4: Global – Breakup of New Cancer Cases by Region (%), 2012
Figure 8-5: Global – Share of US in EPO Market (2014)
Figure 9-1: Market Share of Major Players in the Erythropoietin Market (%), 2014
Figure 9-2: Roche Group – Break up of Revenue by Geography (%), 2014
Figure 9-3: Amgen Inc. – Break up of Revenue by Geography (%), 2014
Figure 9-4: Johnson & Johnson – Break up of Revenue by Geography (%), 2014

List of Tables:

Table 4-1: Some of the Erythropoietin Drugs which are Patented
Table 8-1: US – Sales of Key EPO Products (Billion US$), 2012-2014
Table 8-2: Global – Key Players and Drugs in Erythropoietin Alfa Market (Million US$), 2014
Table 8-3: Global – Key Players and Drugs in Erythropoietin Beta Market (Million US$), 2014
Table 8-4: Global – Key Players and Drugs in Darbepoetin Market (Million US$), 2014
Table 9-1: Roche Group – Key EPO Products
Table 9-2: Roche Group – Financial Performance (Million US$), 2012-2014
Table 9-3: Roche Group – Strengths and Weaknesses
Table 9-4: Amgen Inc. – Key EPO Products
Table 9-5: Amgen Inc. – Key Financials (Million US$), 2012-2014
Table 9-6: Amgen Inc. – Strengths and Weaknesses
Table 9-7: Johnson & Johnson – Key EPO Products
Table 9-8: Johnson & Johnson – Key Financials (Million US$), 2012-2014
Table 9-9: Johnson & Johnson – Strengths and Weaknesses



【レポートのキーワード】

エリスロポエチン

★調査レポート[エリスロポエチンのグローバル市場動向] (コード:RNCS507152)販売に関する免責事項を必ずご確認ください。
★調査レポート[エリスロポエチンのグローバル市場動向]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆